



Giuseppe Auteri

Indirizzo:

Indirizzo e-mail:

Numero di telefono:

Sesso:

Data di nascita:

Nazionalità:

ESPERIENZA LAVORATIVA

[15/03/2020 – Attuale] **Ricercatore universitario**

Principali attività e responsabilità:

Lavoro come Libero Professionista presso il reparto di Ematologia del Policlinico S. Orsola di Bologna, per conto del Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale

[01/11/2019 – Attuale] **Dottorato di Ricerca**

Alma Mater Studiorum

Indirizzo: Bologna, Italia

Principali attività e responsabilità:

Dottorato di ricerca, ciclo XXXV, "Oncologia, Ematologia e Patologia"
Attività assistenziale (diagnostico-terapeutica) rivolta ai pazienti affetti da patologie ematologiche presso l'UO di Ematologia del Policlinico S. Orsola di Bologna, in maniera specifica ai pazienti affetti da Neoplasie Mieloproliferative croniche e Piastrinopenia Immune.

02/11/2015 – 31/10/2019] **Specializzazione in Ematologia**

Ministero dell'Istruzione, dell'Università e della Ricerca

<http://www.aosp.bo.it/>

Indirizzo: Via Pietro Albertoni, 15, 40138, Bologna, Italia

Principali attività e responsabilità:

- management of the oncohematological patient
- management of the patient undergoing HSCT
- management of the patient with MPN
- management of the patient with ITP

01/08/2015 – 31/10/2015] **Medico di continuità assistenziale**

ASP ENNA

Indirizzo: Enna, Italia

Principali attività e responsabilità:

Attività di continuità assistenziale presso l'ASP di Enna, presso il presidio di Agira.

ISTRUZIONE E FORMAZIONE

[06/11/2019] **Specializzazione di Ematologia**

Università di Bologna

Indirizzo: Bologna, Italia

Livello EQF: Livello 8 EQF

Principali materie studiate/competenze professionali acquisite.:
Specializzazione in Ematologia

FINAL EVALUATION: 110/110 + LODE

[10/2014 – 06/2015] **B1 Certificated English Course**

WES

Indirizzo: Belpasso (CT), Italia

[12/02/2015] **Abilitazione alla professione Medica**

Università di Catania

Indirizzo: Catania, Italia

13/10/2008 – 24/10/2014] **Laurea in Medicina e Chirurgia**

Università di Catania

Indirizzo: Catania, Italia

Livello EQF: Livello 7 EQF

Principali materie studiate/competenze professionali acquisite.:
FINAL EVALUATION: 110/110

09/09/2002 – 11/07/2007] **Maturità**

Liceo Socio-psicopedagogico F. De Sanctis, Paternò

Indirizzo: Paternò, Italia

Livello EQF: Livello 4 EQF

Principali materie studiate/competenze professionali acquisite.:
FINAL EVALUATION: 100/100

COMPETENZE LINGUI- STICHE

Lingua madre: italiano

Altre lingue:

inglese

ASCOLTO B2 LETTURA C1 SCRITTURA B2

PRODUZIONE ORALE B2 INTERAZIONE ORALE B2

PUBBLICAZIONI

[2016]

New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment

<https://pubmed.ncbi.nlm.nih.gov/27510853/>

Riferimento: Hematol Oncol

[2018]

Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34 + Cells

<https://pubmed.ncbi.nlm.nih.gov/30116149/>

Riferimento: Mediators Inflamm

[2018]

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

<https://pubmed.ncbi.nlm.nih.gov/30321784/>

Riferimento: Leuk Res

[2019]

Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients

<https://pubmed.ncbi.nlm.nih.gov/30408157/>

Riferimento: Br J Haematol

[2019]

Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis

<https://pubmed.ncbi.nlm.nih.gov/30450539/>

Riferimento: Br J Haematol

[2019]

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

<https://pubmed.ncbi.nlm.nih.gov/30515542/>

Riferimento: Ann Hematol

[2018]

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study

<https://pubmed.ncbi.nlm.nih.gov/30502854/>

Riferimento: Semin Hematol

[2019]

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs

<https://pubmed.ncbi.nlm.nih.gov/30846501/>

Riferimento: Hematologica

[2019]

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

<https://pubmed.ncbi.nlm.nih.gov/30985017/>

Riferimento: Hematol Oncol

[2019]

Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach

<https://pubmed.ncbi.nlm.nih.gov/31359447/>

Riferimento: Hematol Oncol

[2020]

Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years

<https://pubmed.ncbi.nlm.nih.gov/31783273/>

Riferimento: Thromb Res

[2020]

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

<https://pubmed.ncbi.nlm.nih.gov/31860137/>

Riferimento: Cancer

[2020]

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

<https://pubmed.ncbi.nlm.nih.gov/32271957/>

Riferimento: Hematol Oncol

Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms

<https://pubmed.ncbi.nlm.nih.gov/32403407/>

Riferimento: Int J Mol Sci

[2020]

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis

<https://pubmed.ncbi.nlm.nih.gov/32923146/>

Riferimento: Oncoimmunology

[2020]

Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series

<https://pubmed.ncbi.nlm.nih.gov/32979286/>

Riferimento: Hematol Oncol

[2021]

Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients' satisfaction

<https://pubmed.ncbi.nlm.nih.gov/33222149/>

Riferimento: Br J Hematol

[2021]

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

<https://pubmed.ncbi.nlm.nih.gov/33222197/>

Riferimento: Br J Hematol

[2021]

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

<https://pubmed.ncbi.nlm.nih.gov/33414394/>

Riferimento: Blood Cancer J

[2021]

Distinct profile of CD34 + cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease

<https://pubmed.ncbi.nlm.nih.gov/33522952/>

Riferimento: J Exp Clin Cancer Res

[2021]

Impact of comorbidities and body mass index on the outcome of polycythemia vera patients

<https://pubmed.ncbi.nlm.nih.gov/33590502/>

Riferimento: Hematol Oncol

[2021]

Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study

<https://pubmed.ncbi.nlm.nih.gov/33618438/>

Riferimento: Br J Haematol

[2021]

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

<https://pubmed.ncbi.nlm.nih.gov/33794557/>

Riferimento: Cancer

[2021]

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

<https://pubmed.ncbi.nlm.nih.gov/33889952/>

Riferimento: Blood

[2021]

The diagnostic role of Next Generation Sequencing in uncovering isolated splenomegaly: A case report

<https://pubmed.ncbi.nlm.nih.gov/34249291/>

Riferimento: Hematol Rep

[2021]

A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia Vera

<https://pubmed.ncbi.nlm.nih.gov/34638452/>

Riferimento: Cancer (Basel)

[2021]

An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera

<https://pubmed.ncbi.nlm.nih.gov/34900671/>

Riferimento: Front Oncol

RETI E AFFILIAZIONI

Appartenenza a gruppi / associazioni

- Iscrizione alla Società Italiana di Ematologia (ID iscrizione 4539) dal 23/04/2019
- VALDIG (VAscular Liver Disease Group), Università di Bologna, come consulente ematologo.

Clinical trials

- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP). ClinicalTrials.gov Identifier: NCT02077192
- Ruxolitinib observational study in myelofibrosis treated patients in Italy. (ROMEI)
- Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2). ClinicalTrials.gov Identifier: NCT02038036
- Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) ClinicalTrials.gov Identifier: NCT02966353
- Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. ClinicalTrials.gov Identifier: NCT02426086
- Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With MF, Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2). ClinicalTrials.gov Identifier: NCT02101268
- A Study of LY2784544 in Participants With Myeloproliferative Neoplasms. ClinicalTrials.gov Identifier: NCT01594723
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (Low-PV). ClinicalTrials.gov Identifier: NCT03003325
- Eltrombopag in Second Line Adult Primary ITP. ClinicalTrials.gov Identifier: NCT02402998
- A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP (TAPER). ClinicalTrials.gov Identifier: NCT03524612
- A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With MF (MANIFEST). ClinicalTrials.gov Identifier: NCT02158858
- IMG-7289 in Patients With Myelofibrosis. ClinicalTrials.gov Identifier: NCT03136185
- An Efficacy and Safety Study of Fedratinib Compared to BAT in Subjects With DIPSS-Intermediate or High-risk PMF, PPV-MF, PET-MF and Previously Treated With Ruxolitinib (FREEDOM2). ClinicalTrials.gov Identifier: NCT03952039
- Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic ITP. ClinicalTrials.gov Identifier: NCT04278924
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic MF Patients (MOMENTUM). ClinicalTrials.gov Identifier: NCT04173494
- A Phase 3 Study of Pacritinib in Patients With PMF, PPV-MF, or PET-MF (PACIFICA) ClinicalTrials.gov Identifier: NCT03165734
- Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1) ClinicalTrials.gov Identifier: NCT04472598
- Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) ClinicalTrials.gov Identifier: NCT04468984
- A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials. ClinicalTrials.gov Identifier: NCT04064060

[30/06/2020] Advisory Board

- Porpora Trombocitopenica Idiopatica (ITP): Il punto sul trattamento nella pratica clinica.

COMPETENZE PROFESSIONALI

Competenze professionali

A partire dal 2016 mi sono occupato del management dei pazienti affetti da Neoplasie Mieloproliferative Croniche Philadelphia negative (MPN) presso l'UO di Ematologia del Policlinico S.Orsola di Bologna, nello specifico:

- diagnosi delle MPN (Trombocitemia Essenziale, Policitemia Vera, Mielofibrosi)
- valutazione del rischio trombotico e quod vitam
- indicazione al trapianto allogenico di cellule staminali emopoietiche
- gestione della terapia
- raccolta ed elaborazione dati finalizzati alla ricerca scientifica
- partecipazione, come sub-investigatore, a trial clinici rivolti a pazienti affetti da MPN

CERTIFICAZIONI

Certificazioni

- Cambridge English Entry Level Certificate in ESOL International (Entry 3) (Preliminary). 05 Aug 2015
- Basic Life Support - Defibrillation. Bologna 21 Oct 2016
- Intermediate Life Support. Bologna 07 Apr 2021

PRESENTAZIONI

[27/09/2017] PRESENTAZIONI ORALI E LEZIONI

- Regional Meeting about ITP, Splenectomy and Rituximab pros and cons. Bologna 27 Sep 2017
- Myeloproliferative Neoplasms Philadelphia negative. Focus on Polycythemia Vera. Diagnostic criteria. Torino 23 Feb 2018
- Regional Meeting about Polycythemia Vera. Thromboses on PV and the role of ruxolitinib. Bologna 04 Jun 2018
- Regional Meeting about ITP, ITP in elderly patients. Bologna 26 Nov 2018.
- Scientific Meeting of the Seràgnoli Institute. Splanchnic Vein Thromboses and Myeloproliferative Neoplasms. Bologna 24 Jan 2019.
- Meeting with patients with ITP. Why participate in clinical trials. Milano 16 Mar 2019
- Immune Thrombocytopenia: state of art and experience. ITP and surgery. Bologna 27 Jun 2019
- Regional meeting about PV. Resistance criteria to hydroxyurea. Bologna 08 Jul 2019
- Regional Meeting about ITP, About ITP patient and thrombosis. Bologna 18 Nov 2019
- Diagnosi differenziale delle piastrinosi. Lezione a specializzandi di Medicina Interna 2020-2021
- Trombosi Splanchniche e Neoplasie Mieloproliferative Croniche. Lezione a specializzandi di Medicina Interna 2020-2021
- Diagnosi differenziale delle piastrinopenie. Lezione a specializzandi di Medicina Interna 2020-2021
- Terapie di combinazione, pazienti refrattari e nuove terapie dell'ITP. Meeting regionale sull'ITP. Webinar. 18 Nov 2020
- Nuovi paradigmi terapeutici della Policitemia Vera. Meeting scientifici di Istituto. 09 Jan 2021
- COVID-19 e piastrinopenia. Riunione regionale ITP 06 Jun 2021
- Trombocitemia Essenziale, terapia di combinazione e nuovi farmaci. Progetto Ematologia Romagna 16 Oct 2021
- Caplacizumab: caratteristiche funzionali e studi registrativi. Riunion regionale sulla PTT. FAD sincrona 22 Nov 2021
- Lezione MMG Ordine dei medici di Bologna. 04 Nov 2021
- Advanced ITP Discussion. La scelta del TPO mimetico. Milano 20 Nov 2021

CONFERENCES AND MEETING

Conferences and meeting

- Advanced ITP Discussion project. Bari 27-28 Nov 2015
- ReTHINK Global Investigator Meeting. Barcelona 15 Apr 2016
- New Drugs in Hematology. Bologna 9 May 2016
- SIE Congress. Rome 15-18 Oct 2017
- News about American Society of Haematology meeting. Milan 08-10 Mar 2018
- New Drugs in Hematology. Bologna 1-3 Oct 2018
- ARES National Investigator Meeting. Rome 12 Nov 2018
- News about American Society of Haematology meeting. Bologna 14-16 Feb 2018
- SIE Congress. Rome 07-09 Oct 2019
- Advance Discussion in ITP. Sorrento 15-16 Nov 2019
- Advance Discussion in ITP. Milano 04 Nov 2021

CORSI

Corsi

- 4th National Course of Interactive Hematology. Catania 6 - 7 Feb 2015
- Interactive Lesson of Hematology. Catania 2 Oct 2015
- GITMO Educational Course. New Drugs and transplant. Udine 21-22 Jan 2016
- Hematological Romagna's Saturdays. Faenza 14 May 2016
- How communicate scientific knowing. Bologna 28 Oct 2016
- Talking about Myelofibrosis and MPNs. Bologna 21 Nov 2016
- Romagna's haematologic project 2017
- Meet the Experts on MPNs: from the bench to the bedside. 25-27 May 2017
- Romagna's haematologic project 2018
- Masterclass on Myeloproliferative Neoplasms. Florence 03-04 May 2018
- MDS: diagnosis, prognosis and therapy. Bologna 06 Oct 2018
- Romagna's haematologic project 2019
- Romagna's haematologic project 2020
- Romagna's haematologic project 2021

[2017 - Attuale] **Societa Italiana di Ematologia (SIE)**

- COMORBIDITY AND BODY MASS INDEX IN PATIENTS WITH POLYCYTHEMIA VERA: A PV-NET STUDY. SIE 2019
- CYTOGENETIC ABNORMALITIES IN PRIMARY MYELOFIBROSIS: CLINICAL ASSOCIATION AND OUTCOME IN AN ITALIAN MULTICENTER SERIES. SIE 2019
- ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO ACHIEVE LONG-TERM REMISSION. UPDATED RESULTS OF A PHASE II, MULTICENTER, PROSPECTIVE STUDY BY GIMEMA GROUP (THE ESTIT STUDY). SIE 2019
- SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB. SIE 2019
- RISK FACTORS FOR PROGRESSION TO BLAST PHASE IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB; AN ITALIAN STUDY ON 589 PATIENTS. SIE 2019
- IMMUNE THROMBOCYTOPENIA IN THE ELDERLY. A MULTICENTER ITALIAN STUDY ON 524 PATIENTS. SIE 2019
- POLYCYTHEMIA VERA AND PRIMARY MYELOFIBROSIS: TOWARDS A PERSONALIZED THERAPY. SIE 2017

[2018 - Attuale] **Societa Italiana di Ematologia Sperimentale (SIES)**

- TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS. SIES 2018
- CIRCULATING CD34+STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS. SIES 2018

- First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. ASH 2020
- Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. ASH 2020
- Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. ASH 2020
- The Infection-Driven Production/Secretion of Inflammatory Cytokines By Circulating Monocytes of Myelofibrosis Is Defective and Is Reactivated after In Vivo JAK1/2 Inhibition. ASH 2019
- Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. ASH 2019
- Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. ASH 2019
- Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. ASH 2019
- The Malignant Hemopoietic Clone of Triple Negative Patients with Myelofibrosis Shows in Vitro Functional Defects but Is Highly Responsive to the Pro-Survival Signals of Circulating Autologous Microvesicles. ASH 2018
- Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). ASH 2018
- Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues. ASH 2018
- Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients. ASH 2018
- Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. ASH 2018
- Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. ASH 2018
- Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2(V617F) Mutation, High Disease Burden and Ruxolitinib Response. ASH 2017
- Aging Significantly Drives Decision Making and Outcome in Immune Thrombocytopenia Patients: A Monocentre Study on 508 Patients. ASH 2017

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".

Bologna, 01/02/2022

